The effectiveness of stereotactic gamma-radiosurgery for treating acoustic neurinoma was evaluated by measuring the volumes of the tumor, non-enhanced tumor, and cerebellar edema in 13 patients with acoustic neurinoma who were followed up for 9 to 15 months (median 12.7 mos) after treatment. The tumor volume and non-enhanced volume tended to reach a maximum after 6 months, and cerebellar edema volume after 9 months, then decreased gradually thereafter. Hearing loss tended to in crease gradually, but involvement of the facial nerve was transient.
Introduction
Stereotactic gamma-radiosurgery, which can focus collimated gamma rays from 201 60Co sources into a small volume, is widely used to treat intracranial le sions such as arteriovenous malformation, acoustic neurinoma, and other neoplasms.3'5'6,10'1.1,18) Acoustic neurinoma shrinks and demonstrates less contrast enhancement on magnetic resonance (MR) images after stereotactic radiosurgery.
Obliteration of the blood supply to the tumor caused by radiation induced vascular injury may be the most important mechanism controlling tumor growth. 2, 8, 9, 12, 16, 19 ) However, only the average tumor diameter was measured in most cases and few precise volumetric analyses have been performed. This study measured the change in whole tumor and non-enhanced volumes and the functions of the acoustic, facial, and trigeminal nerves during the ear ly posttreatment stage.
Patients and Methods
This study evaluated 13 patients with acoustic neurinoma treated with stereotactic radiosurgery and followed up for 9 to 15 months (median 12.7 mos) after treatment (Table 1) . Radiosurgery was perform Table 1 Clinical  characteristics  of acoustic  neurino   ma patients ed with a Leksell gamma unit (Elekta Instruments, Stockholm, Sweden) using a marginal dose below 15 Gy, almost 50% of the maximum dose, to avoid radiation injury to the trigeminal, facial, and acoustic nerves. MR imaging studies were carried out for 9 to 15 months (median 12.8 mos) after treatment in 12 of the 13 patients, and the acoustic, facial, and trigeminal nerve functions were evalu ated for 6 to 12 months (median 9.9 mos) after treatment in seven of these 12 patients.
Serial gadolinium (Gd)-enhanced T1 and T, weighted MR images were taken with 3 mm-thick slices before and 3, 6, 9, 12, and 15 months after treatment.
The volumes of the tumor, the non enhanced area, and the cerebellar edema were calculated by integrating the area of the lesion in each slice multiplied by the slice thickness (3 mm) us ing the Image 1.47 software (Apple Computer Inc., Cupertino, Cal., U.S.A.).
Hearing was evaluated with a pure-tone audiogram (250, 500, 1000, 2000, and 4000 Hz) for air conduction before and 3, 6, 9, and 12 months after treatment.
Changes in volume and hearing function were statistically analyzed with Dunnett's test, and p < 0.05 was considered significant. 
Results
The tumor volume tended to increase slightly 6 months after radiosurgery and to decrease to al most the same volume as pretreatment after 9
months. The tumor volume was stable in seven pa tients, slightly increased in three, and decreased in three during the follow-up of 9-15 months (Fig. 1) . The non-enhanced tumor volume reached the max imum (44.2% of total tumor volume) after 6 months and decreased thereafter (p < 0.01). Ab sence of central enhancement increased in all pa tients, appearing in five and increasing in another eight compared to pretreatment during the follow up of 9-15 months.
The volume of cerebellar edema tended to reach a maximum after 9 months and decreased thereafter (not significant). New cere bellar edema developed in only one patient of the seven without cerebellar edema before radiosurgery, and pretreatment edema increased in another five pa tients during the follow-up of 9-15 months. How ever, the edema was transient and caused no symp toms in any patient. A representative case which re sponded well to the treatment is shown in Fig. 2 . The tumor volume decreased markedly 15 months after treatment, while the non-enhanced volume in creased prominently after 6 months and decreased after 15 months.
Hearing loss gradually increased in almost all fre quency bands after treatment (not significant) (Fig.  3) . The average hearing loss in the 250 to 4000-Hz bands was stable after radiosurgery in three patients whose pretreatment hearing losses were over or equal to 80 dB, and increased in four patients whose pretreatment hearing losses were under 80 dB. Figure 4 shows the changes with time in acoustic, facial, and trigeminal nerve function, and tumor and edema volume in seven patients. Sensory disturbance on the face deteriorated gradually after radiosurgery in one patient, improved in two, and was stable in 
Discussion
Our MR imaging study showed that acoustic neurinoma volume tended to increase transiently 6 months after radiosurgery treatment. The follow-up was too short to evaluate the long-term effects of the treatment, but we expect tumor shrinkage to occur during further follow-up.4,1,9,1215,17'19) Loss of central tumor enhancement occurred in all patients, and the non-enhanced volume increased significantly 6 months after treatment, although decreasing again after 15 months. Linskey et al.') reported a similar course, with loss of central tumor enhancement in 78% of cases between 1 and 18 months (median 6 mos) after gamma-radiosurgery, while 17% of patients with decreased central en hancement showed a reincrease 6 to 29 months (me dian 13 mos) later. Such loss of central contrast en hancement may result from radiation-induced vas cular injury and occlusion.9,'3) New cerebellar edema developed in only one of our 12 patients, but caused no additional symptoms. Edema tended to reach a maximum after 9 months, almost agreeing with Linskey et a1.9' who found 9% of patients developed new adjacent parenchymal changes (edema) 5 to 15 months (median 8 mos) after treatment, which normalized 13 to 19 months later in 25% of cases. The maximization of cerebellar edema Nerve dysfunction is shown as the black column while the white column in dicates no symptoms. Previous operative treat ment and maximum/marginal irradiation doses are: 69-year-old female, operation (-) and 30/18 Gy (A); 36-year-old female, opera tion (-) and 25/15 Gy (B); 65-year-old female, operation (+) and 25/11 Gy (C); 59 year-old female, operation (+) and 30/15 Gy (D); 42-year-old male, operation (-) and 28/ 14 Gy (E); 66-year-old female, operation (-) and 36/18 Gy (F); 54-year-old female, opera tion (+) and 28/14 Gy (G). occurred 3 months after the greatest volumes of tumor and non-enhanced portion were reached. Hearing loss tended to increase gradually after radiosurgery.
New facial nerve dysfunction devel oped in one of seven patients and the previous dysfunction deteriorated in another, but was tran sient in both. Previous trigeminal nerve dysfunction deteriorated in one patient, but improved in two. Linskey et a1.9' found that useful hearing preserva tion (pure-tone average threshold < 50 dB and speech discrimination > 50%) was achieved in 50% of patients after 6 months and 38% after 1 year, and loss of useful hearing began 1 week to 12 months (median 6 mos) after treatment.
New facial nerve dysfunction occurred in 22% after 6 months and 30% after 1 year, beginning after 1 day to 16 months (median 5 mos), but completely disappear ed in 20% and improved in 53% of patients after 1 to 9 months (median 6 mos). New trigeminal nerve dysfunction appeared in 19% of patients after 6 months and 33% after 1 year, starting after 2 to 19 months (median 6 mos). Only 10% of new trigeminal neuropathy resolved completely, but the majority of patients improved to varying degrees. Dysfunction of cranial nerves is thought to be related to demyeli nation or compromised vascular supply, but the sensitivity to radiosurgery varies among the cranial nerves. 1,9,14) Stereotactic radiosurgery apparently controls tumor growth with relatively low risk and is an attrac tive method, especially for patients who are elderly, have medical problems, or refuse surgery. Further follow-up is necessary for the assessment of this new treatment modality. -1106 - , 1990 
